Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of ...

A compound derived from Nectandra leucantha ... they arrived at a more potent molecule whose mean plasma half-life reached 21 ...

NodThera’s pipeline includes three drug candidates and other compounds in ... NT-0249 is a novel molecule that exhibits sub-micromolar blood potency and optimized plasma protein binding to ...

SHANGHAI, May 4, 2025 /PRNewswire/ -- On April 23, 2025, Nutshell Therapeutics ( Shanghai ) Co., LTD. received IND clearance from the FDA to initiate Phase 1 clinical trial in the United States for ...

Additional compounds to be evaluated in the trial are expected to be ... with therapeutic effects on plasma and cerebrospinal fluid biomarkers and supportive clinical signals showing the potential ...

The team conducted comprehensive analyses of blood plasma compounds from mice following intense treadmill running. The most significantly induced molecule was a modified amino acid called Lac-Phe.

Building on this evidence, we have synthesized novel, potent and selective small-molecule antagonists to target CX3CR1 and have provided pre-clinical validation of their activity in animal models with ...